The HLA-E Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population in which the HLA-E gene has been disrupted in the human Jurkat T-lymphocyte cell line. This heterogeneous pool arises from a spectrum of gene editing events, collectively leading to loss of functional HLA-E protein. The polyclonal format preserves genetic diversity, providing a robust, population-level model for functional studies while minimizing clonal selection artifacts.
The Jurkat cell line, originally derived from a patient with T-cell leukemia, is a widely used human T-lymphocyte model that recapitulates T-cell receptor signaling, cytokine production, and effector functions. Its leukemic background makes it particularly relevant for investigating mechanisms of tumor immune escape, including those involving immunoregulatory molecules such as HLA-E.
HLA-E is a non-classical MHC class I molecule that serves as a ligand for the CD94/NKG2 family of receptors expressed on natural killer (NK) cells and a subset of CD8+ T cells. It selectively presents nonamer peptides derived from the signal sequences of classical MHC class I molecules, a process dependent on the peptide transporter TAP, tapasin, calreticulin, and beta-2 microglobulin. Engagement of the inhibitory receptor CD94/NKG2A by peptide-bound HLA-E suppresses NK and T-cell cytotoxicity through the activation of SHP-1 and SHP-2 phosphatases, while the activating receptor CD94/NKG2C can stimulate effector functions under certain conditions. HLA-E expression is transcriptionally regulated by cytokines such as IFN-gamma and IFN-alpha via STAT1 and NF-kB pathways, and is also modulated by TGF-beta. This signaling axis represents a critical checkpoint in immune surveillance, where normal classical MHC I expression prevents unwanted killing, but its downregulation??common in tumors??can deprive HLA-E of peptide ligands, potentially altering NK cell responses.
In Jurkat T-leukemia cells, endogenous HLA-E contributes to immune evasion by engaging NKG2A on NK cells and inhibiting their cytotoxic activity. Disruption of HLA-E in this context thus generates a valuable loss-of-function model for dissecting how leukemia cells escape innate immune control. The polyclonal knockout population allows researchers to assess the functional impact of HLA-E deficiency across a heterogeneous cell pool, avoiding the biases of single-cell clones and better reflecting the native diversity of tumor?Cimmune interactions. This model is especially suited for exploring strategies to enhance NK cell-mediated clearance of T-cell leukemia.
These HLA-E knockout cells enable a range of functional assays, including flow cytometry for confirmation of HLA-E surface loss, NK cell cytotoxicity and degranulation (CD107a) assays to quantify increased sensitivity to killing, and Western blotting or RT-qPCR for molecular analysis. Research applications include mechanistic studies of cancer immune evasion, screening of immunomodulatory compounds that disrupt the HLA-E/NKG2A interaction, and investigation of viral persistence where pathogens exploit this inhibitory pathway. The polyclonal nature also supports screening approaches where variable gene editing outcomes may reveal dose-dependent or variant-specific effects on immune regulation. By eliminating HLA-E expression, this knockout system provides a rigorous tool for delineating the specific roles of HLA-E in immune tolerance and tumor surveillance. For further details, please contact Ascent Research.
